GlassScriptPhysician profile
Alison A Smith
NPI 1164841706
$29,121.35
in general payments reported to CMS, 2019-2025
28 companies · $18K in 2025
The $18K reported for 2025 was more than what 98% of Trauma Surgery providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $831 · 2021: $335 · 2022: $610 · 2023: $5,908 · 2024: $1,832 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $4,249 · Education: $2,500 · Consulting Fee: $2,050 · Travel and Lodging: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,850.00 |
| Food and Beverage | $4,249.23 |
| Education | $2,500.00 |
| Consulting Fee | $2,050.00 |
| Travel and Lodging | $1,334.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $19,379.88 | 2022-2025 | |
| Intuitive Surgical, INC. | $4,848.79 | 2019-2024 | Davinci Xi, Da Vinci Surgical System |
| Prytime Medical Devices, INC. | $1,680.55 | 2021-2025 | Er-Reboa Plus, Preboa-Pro |
| Zimmer Biomet Holdings, INC. | $843.89 | 2024 | Advantagerib |
| Medical Device Business Services, INC. | $830.55 | 2020 | |
| Polynovo North America LLC | $283.88 | 2024-2025 | Novosorb Btm |
| Teleflex LLC | $198.14 | 2025 | Quikclot, Arrow |
| Biocomposites INC | $149.89 | 2025 | Stimulan |
| Haemonetics Corporation | $119.92 | 2025 | Teg6s Hemostasis System |
| Urgo Medical North America, LLC | $117.58 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Shire North American Group INC | $113.61 | 2019 | |
| Integra Lifesciences Corporation | $84.10 | 2021 | |
| Davol INC. | $63.09 | 2025 | Progel Applicator Spray Tips |
| Abiomed | $62.99 | 2024 | Impella |
| Pacira Pharmaceuticals Incorporated | $46.50 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $43.21 | 2025 | Vistaseal |
| Becton, Dickinson and Company | $36.77 | 2023 | Phasix Mesh |
| Octapharma USA, INC. | $30.77 | 2025 | Fibryga |
| Kci USA, INC. | $27.11 | 2021 | |
| Abbott Laboratories | $26.36 | 2025 | Alinity |
| Abbvie INC. | $26.21 | 2021-2022 | |
| Innovation Technologies INC | $25.09 | 2024 | Irrisept |
| Allergan, INC. | $24.57 | 2021 | |
| Reprise Biomedical, INC. | $20.26 | 2025 | Miro 3d |
| Vertex Pharmaceuticals Incorporated | $19.20 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.44 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.